Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody-guided individualized immunosuppressive therapy in primary membranous nephropathy
NL-OMON28712Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of cyclophosphamide, mycophenolic acid, tacrolimus, prednisone and rituximab in idiopathic membranous glomerulonephritis (IMG) (4 arms), sponsored by Radboud University Medical Center. Primary endpoint: Cumulative incidence of remission. Started Aug 2013; status: recruiting.
02
Drugs
cyclophosphamidemycophenolic acidtacrolimusprednisonerituximab
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on NL-OMON28712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28712.